Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 19, 2024Blood Cancer Discovery

Abstract PO-034: Targeting metabolic plasticity and flexibility via SIRT3 inhibition to restrain nucleotides availability in DLBCLs

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMeng LiGuangxi Medical UniversityNPNoel R. ParkPrinceton UniversityCCChris Chin

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e64292b6db6435875d3eabhttps://doi.org/10.1158/2643-3249.lymphoma24-po-034
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enhancing Immunotherapy in Diffuse Large B-Cell Lymphoma: The Synergistic Potential of Metabolic Checkpoint Inhibitors and Immunomodulation2026 · 1 citations
  2. 2A Mitochondria-Targeting SIRT3 Inhibitor with Activity against Diffuse Large B Cell Lymphoma2024 · 18 citations
  3. 3Metabolic vulnerabilities and therapeutic opportunities in diffuse large B-cell lymphoma2026 · 1 citations
  4. 4Abstract 392: EMT-like reprogramming drives drug-tolerant persister cell plasticity in mantle cell lymphoma via ribosome biogenesis.2026
  5. 5Abstract A018: EMT-like reprogramming defines drug-tolerant persister cell plasticity in mantle cell lymphoma2026